losartan has been researched along with Acantholysis Bullosa in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of losartan in the prevention of restenosis after BD of esophageal stenosis in children with DEB." | 8.31 | Our experience of using Losartan for esophageal stenosis in children with dystrophic form of congenital epidermolysis bullosa. ( Abaykhanov, R; Budkina, T; Dyakonova, E; Fisenko, A; Gusev, A; Lokhmatov, M; Murashkin, N; Oldakovskiy, V; Tupylenko, A; Yatzik, S, 2023) |
| "To evaluate the efficacy of losartan in the prevention of restenosis after BD of esophageal stenosis in children with DEB." | 4.31 | Our experience of using Losartan for esophageal stenosis in children with dystrophic form of congenital epidermolysis bullosa. ( Abaykhanov, R; Budkina, T; Dyakonova, E; Fisenko, A; Gusev, A; Lokhmatov, M; Murashkin, N; Oldakovskiy, V; Tupylenko, A; Yatzik, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Relvas, M | 1 |
| Figueiredo, AC | 1 |
| Calado, R | 1 |
| Calvão, J | 1 |
| Ramos, L | 1 |
| Oldakovskiy, V | 1 |
| Murashkin, N | 1 |
| Lokhmatov, M | 1 |
| Gusev, A | 1 |
| Tupylenko, A | 1 |
| Budkina, T | 1 |
| Yatzik, S | 1 |
| Dyakonova, E | 1 |
| Abaykhanov, R | 1 |
| Fisenko, A | 1 |
| Uitto, J | 1 |
| Vahidnezhad, H | 1 |
3 other studies available for losartan and Acantholysis Bullosa
| Article | Year |
|---|---|
Losartan as therapy for recessive dystrophic epidermolysis bullosa: Report of three cases.
Topics: Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Humans; Losartan; Skin | 2022 |
Our experience of using Losartan for esophageal stenosis in children with dystrophic form of congenital epidermolysis bullosa.
Topics: Adolescent; Child; Child, Preschool; Constriction, Pathologic; Epidermolysis Bullosa; Epidermolysis | 2023 |
Losartan for treatment of epidermolysis bullosa: A new perspective.
Topics: Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Humans; Losartan | 2021 |